Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis.

Pothoulakis C, Torre-Rojas M, Duran-Padilla MA, Gevorkian J, Zoras O, Chrysos E, Chalkiadakis G, Baritaki S.

Int J Cancer. 2018 Jan 15;142(2):334-346. doi: 10.1002/ijc.31064. Epub 2017 Oct 12.

PMID:
28929494
2.

Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer.

Wottrich S, Kaufhold S, Chrysos E, Zoras O, Baritaki S, Bonavida B.

Drug Resist Updat. 2017 Jan;30:28-38. doi: 10.1016/j.drup.2017.01.001. Epub 2017 Jan 9. Review.

PMID:
28363333
3.

Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis.

Hoffman JM, Baritaki S, Ruiz JJ, Sideri A, Pothoulakis C.

Am J Pathol. 2016 Jan;186(1):134-44. doi: 10.1016/j.ajpath.2015.09.013. Epub 2015 Nov 18.

4.

Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/Stat3 signaling.

Rodriguez JA, Huerta-Yepez S, Law IK, Baay-Guzman GJ, Tirado-Rodriguez B, Hoffman JM, Iliopoulos D, Hommes DW, Verspaget HW, Chang L, Pothoulakis C, Baritaki S.

Cell Mol Gastroenterol Hepatol. 2015 Nov 1;1(6):610-630.

5.

Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.

Huerta-Yepez S, Liu H, Baritaki S, Del Lourdes Cebrera-Muñoz M, Rivera-Pazos C, Maldonado-Valenzuela A, Valencia-Hipolito A, Vega MI, Chen H, Berenson JR, Bonavida B.

Int J Oncol. 2014 Sep;45(3):1184-92. doi: 10.3892/ijo.2014.2511. Epub 2014 Jun 20.

PMID:
24970600
6.

Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis.

Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S.

For Immunopathol Dis Therap. 2013;4(1). doi: 10.1615/ForumImmunDisTher.2013008299.

7.

Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer.

Huerta-Yepez S, Baritaki S, Baay-Guzman G, Hernandez-Luna MA, Hernandez-Cueto A, Vega MI, Bonavida B.

Nitric Oxide. 2013 Feb 28;29:17-24. doi: 10.1016/j.niox.2012.12.001. Epub 2012 Dec 11.

PMID:
23246440
8.

Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.

Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC.

Cancer Res. 2012 Jun 15;72(12):3091-104. doi: 10.1158/0008-5472.CAN-11-3546. Epub 2012 Apr 13.

9.

TRAF6 activation in multiple myeloma: a potential therapeutic target.

Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B.

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):155-63. doi: 10.1016/j.clml.2012.01.006. Epub 2012 Mar 21. Review.

10.

Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.

Martinez-Paniagua MA, Vega MI, Huerta-Yepez S, Baritaki S, Vega GG, Hariharan K, Bonavida B.

Mol Cancer Ther. 2012 Mar;11(3):572-81. doi: 10.1158/1535-7163.MCT-11-0635. Epub 2012 Jan 19.

11.

Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies.

Bonavida B, Huerta-Yepez S, Baritaki S, Vega M, Liu H, Chen H, Berenson J.

Crit Rev Oncog. 2011;16(3-4):261-7. Review.

PMID:
22248059
14.

Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.

Martínez-Paniagua MA, Baritaki S, Huerta-Yepez S, Ortiz-Navarrete VF, González-Bonilla C, Bonavida B, Vega MI.

Cell Cycle. 2011 Aug 15;10(16):2792-805. Epub 2011 Aug 15.

15.

The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.

Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B.

Int J Oncol. 2011 Jun;38(6):1683-94. doi: 10.3892/ijo.2011.984. Epub 2011 Mar 23.

PMID:
21455568
16.

Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma.

Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B.

For Immunopathol Dis Therap. 2011 Apr 1;2(2). doi: 10.1615/ForumImmunDisTher.v2.i2.90.

17.

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA.

Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. Review.

18.

Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.

Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS.

Cancer Res. 2011 Feb 15;71(4):1406-17. doi: 10.1158/0008-5472.CAN-10-1296. Epub 2010 Dec 15. Retraction in: Cancer Res. 2017 Jul 1;77(13):3718.

19.

Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP.

Baritaki S, Huerta-Yepez S, Sahakyan A, Karagiannides I, Bakirtzi K, Jazirehi A, Bonavida B.

Cell Cycle. 2010 Dec 15;9(24):4931-40. Epub 2010 Dec 15.

20.

A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells.

Vega MI, Baritaki S, Huerta-Yepez S, Martinez-Paniagua MA, Bonavida B.

Leuk Lymphoma. 2011 Jan;52(1):108-21. doi: 10.3109/10428194.2010.531408. Epub 2010 Dec 6.

PMID:
21133714
21.

Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: ineffectiveness of carbapenems and increasing resistance to colistin.

Neonakis IK, Samonis G, Messaritakis H, Baritaki S, Georgiladakis A, Maraki S, Spandidos DA.

Chemotherapy. 2010;56(6):448-52. doi: 10.1159/000320943. Epub 2010 Nov 18.

PMID:
21088396
22.

Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-κB/Snail/YY1/RKIP circuitry.

Bonavida B, Baritaki S.

Nitric Oxide. 2011 Jan 1;24(1):1-7. doi: 10.1016/j.niox.2010.10.001. Epub 2010 Oct 8. Review.

PMID:
20933602
23.

The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit.

Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B.

Genes Cancer. 2010 May;1(5):409-420.

24.

Mycobacterium arupense pulmonary infection: antibiotic resistance and restriction fragment length polymorphism analysis.

Neonakis IK, Gitti Z, Kontos F, Baritaki S, Petinaki E, Baritaki M, Liakou V, Zerva L, Spandidos DA.

Indian J Med Microbiol. 2010 Apr-Jun;28(2):173-6. doi: 10.4103/0255-0857.62502.

25.
26.

Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.

Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B.

Cancer Res. 2009 Nov 1;69(21):8376-85. doi: 10.1158/0008-5472.CAN-09-1069. Epub 2009 Oct 20.

27.

Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.

Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B.

Oncogene. 2009 Oct 8;28(40):3573-85. doi: 10.1038/onc.2009.214. Epub 2009 Jul 27.

PMID:
19633685
28.

Mycobacterium thermoresistibile: case report of a rarely isolated mycobacterium from Europe and review of literature.

Neonakis IK, Gitti Z, Kontos F, Baritaki S, Petinaki E, Baritaki M, Zerva L, Spandidos DA.

Indian J Med Microbiol. 2009 Jul-Sep;27(3):264-7. doi: 10.4103/0255-0857.53214. Review.

29.
30.

Report of 2 indigenous cases of leprosy from a European country: use of polymerase chain reaction-restriction fragment length polymorphism analysis of hsp65 gene for identification of Mycobacterium leprae directly from a clinical sample.

Neonakis IK, Gitti Z, Kontos F, Baritaki S, Zerva L, Krambovitis E, Spandidos DA.

Diagn Microbiol Infect Dis. 2009 Jul;64(3):331-3. doi: 10.1016/j.diagmicrobio.2009.03.006. Epub 2009 Apr 18.

PMID:
19376672
31.

BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma.

Zaravinos A, Kanellou P, Baritaki S, Bonavida B, Spandidos DA.

Cell Cycle. 2009 May 1;8(9):1402-8. Epub 2009 May 26.

PMID:
19342899
32.

YY1 Over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels.

Baritaki S, Chatzinikola AM, Vakis AF, Soulitzis N, Karabetsos DA, Neonakis I, Bonavida B, Spandidos DA.

Cancer Invest. 2009 Feb;27(2):184-92. doi: 10.1080/07357900802210760.

PMID:
19235591
33.

Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.

Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, Bonavida B.

Nitric Oxide. 2009 Feb;20(1):39-52. doi: 10.1016/j.niox.2008.08.001. Epub 2008 Aug 22.

PMID:
18778787
34.

K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma.

Lyronis ID, Baritaki S, Bizakis I, Krambovitis E, Spandidos DA.

Pathol Oncol Res. 2008 Sep;14(3):267-73. doi: 10.1007/s12253-008-9032-1. Epub 2008 Jul 1.

PMID:
18592405
35.

Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases.

Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D, Yeung K.

Nitric Oxide. 2008 Sep;19(2):152-7. doi: 10.1016/j.niox.2008.04.018. Epub 2008 Apr 24. Review.

PMID:
18477483
36.

Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.

Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B.

J Immunol. 2008 May 1;180(9):6199-210.

37.

High prevalence of Human Herpes Virus 8 (HHV-8) in patients with Warthin's tumors of the salivary gland.

Dalpa E, Gourvas V, Baritaki S, Miyakis S, Samaras V, Barbatis C, Sourvinos G, Spandidos DA.

J Clin Virol. 2008 Jun;42(2):182-5. doi: 10.1016/j.jcv.2008.01.015. Epub 2008 Mar 14.

PMID:
18339579
38.

Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.

Kanellou P, Zaravinos A, Zioga M, Stratigos A, Baritaki S, Soufla G, Zoras O, Spandidos DA.

Cancer Lett. 2008 Jun 8;264(1):145-61. doi: 10.1016/j.canlet.2008.01.042. Epub 2008 Mar 10.

PMID:
18331779
39.

Analysis of the beta-lactam resistance phenotypes of Escherichia coli. An 8-year survey conducted in Greece.

Neonakis IK, Baritaki S, Georgiladakis A, Spandidos DA.

Roum Arch Microbiol Immunol. 2008 Jan-Jun;67(1-2):10-3.

PMID:
19284160
40.

Activation-induced cell death signalling in CD4+ T cells by staphylococcal enterotoxin A.

Porichis F, Morou A, Baritaki S, Spandidos DA, Krambovitis E.

Toxicol Lett. 2008 Jan 4;176(1):77-84. Epub 2007 Dec 3.

PMID:
18054450
41.
42.

Mycobacterial species diversity at a general hospital on the island of Crete: first detection of Mycobacterium lentiflavum in Greece.

Neonakis IK, Gitti Z, Kourbeti IS, Michelaki H, Baritaki M, Alevraki G, Papadomanolaki E, Tsafaraki E, Tsouri A, Baritaki S, Krambovitis E, Spandidos DA.

Scand J Infect Dis. 2007;39(10):875-9.

PMID:
17852893
43.

The NO TRAIL to YES TRAIL in cancer therapy (review).

Lee JY, Huerta-Yepez S, Vega M, Baritaki S, Spandidos DA, Bonavida B.

Int J Oncol. 2007 Oct;31(4):685-91. Review.

PMID:
17786298
44.

Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.

Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, Berenson JR.

Br J Haematol. 2007 Aug;138(4):467-78. Epub 2007 Jun 22.

PMID:
17587338
45.

Resistance status of Mycobacterium tuberculosis on the island of Crete, Greece.

Neonakis IK, Gitti Z, Baritaki M, Kourbeti IS, Baritaki S, Petinaki E, Maraki S, Krambovitis E, Spandidos DA.

Eur J Clin Microbiol Infect Dis. 2007 Aug;26(8):607-9. No abstract available.

PMID:
17587069
46.
47.

CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators.

Apostolakis S, Krambovitis E, Vlata Z, Kochiadakis GE, Baritaki S, Spandidos DA.

Thromb Res. 2007;121(3):387-95. Epub 2007 May 23.

PMID:
17521710
48.

Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications.

Baritaki S, Apostolakis S, Kanellou P, Dimanche-Boitrel MT, Spandidos DA, Bonavida B.

Adv Cancer Res. 2007;98:149-90. Review.

PMID:
17433910
49.

Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.

Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B.

Mol Cancer Ther. 2007 Apr;6(4):1387-99.

50.

Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth.

Chen H, Gordon MS, Campbell RA, Li M, Wang CS, Lee HJ, Sanchez E, Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida B, Berenson JR.

Blood. 2007 Jul 1;110(1):287-95. Epub 2007 Mar 16.

Supplemental Content

Loading ...
Support Center